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The genetic basis of inter-individual variation in recovery from
traumatic brain injury
Daniel Cortes1 and Martin F. Pera 1✉
Traumatic brain injury (TBI) is one of the leading causes of death among young people, and is increasingly prevalent in the aging
population. Survivors of TBI face a spectrum of outcomes from short-term non-incapacitating injuries to long-lasting serious and
deteriorating sequelae. TBI is a highly complex condition to treat; many variables can account for the observed heterogeneity in
patient outcome. The limited success of neuroprotection strategies in the clinic has led to a new emphasis on neurorestorative
approaches. In TBI, it is well recognized clinically that patients with similar lesions, age, and health status often display differences in
recovery of function after injury. Despite this heterogeneity of outcomes in TBI, restorative treatment has remained generic. There is
now a new emphasis on developing a personalized medicine approach in TBI, and this will require an improved understanding of
how genetics impacts on long-term outcomes. Studies in animal model systems indicate clearly that the genetic background plays
a role in determining the extent of recovery following an insult. A candidate gene approach in human studies has led to the
identification of factors that can influence recovery. Here we review studies of the genetic basis for individual differences in
functional recovery in the CNS in animals and man. The application of in vitro modeling with human cells and organoid cultures,
along with whole-organism studies, will help to identify genes and networks that account for individual variation in recovery from
brain injury, and will point the way towards the development of new therapeutic approaches.
npj Regenerative Medicine             (2021) 6:5 ; https://doi.org/10.1038/s41536-020-00114-y
INTRODUCTION
Traumatic brain injury (TBI) is any encephalic damage caused by
an external mechanical force, usually acute. The causes of such
damage include automotive collisions, falls, blunt impacts,
projectiles, and diverse other insults, and the mechanism and site
of TBI are thus highly variable. A total of 50 million people
experience TBI annually throughout the world, with the global
cost to the economy estimated at $US 400 billion per annum1.
One of the major concerns regarding TBI is its impact on families
and societies. TBI is the leading cause of death in young
productive people, and its incidence is increasing in the aging
population2. TBI presents an immense challenge to the health care
delivery system in low- and middle-income nations3. The sequelae
of TBI can be long-lasting and sometimes permanent4; strategies
that could mitigate the impairment resulting from TBI could
greatly increase the quality of life and enable a faster return to
productivity.
TBI can be classified in many ways according to the cause,
severity, brain volume affected, and other parameters. Although
the primary insult can account for the greater damage in the
brain, the so-called “secondary injury” plays a vital role during the
later phase of survival when other factors such as inflammation,
edema, and ischemia/reperfusion, affect injury outcome. TBI
causes acute disruption of cytoarchitecture, diffuse axonal injury,
dendrite shearing, synapse disruption, and demyelination, some-
times increased by hematoma-induced compression, white matter
loss, and further damage in following stages due to necrosis,
apoptosis, and inflammation5,6.
It is well known that individual patients can show very different
degrees of outcome and functional recovery from TBI or stroke,
even when clinical variables such as the anatomical site and
nature and extent of the lesion, patient age, and overall health
status, are taken into consideration7. In TBI and stroke, because
extensive clinical trials of interventions aimed at neuroprotection
have not been overly successful, there is an increasing emphasis
on neuro-rehabilitative therapies to enhance recovery8, and a new
focus on a precision medicine approach to patient treatment1.
Currently, there is little in the way of evidence-based guidelines
for surgical treatment or rehabilitative interventions in TBI9.
The goal of applying precision medicine to enhance recovery
from brain injury is challenging at present, because although
outcomes following stroke or TBI are highly variable, the basis for
this variation is largely unknown. Animal studies, discussed below,
have clearly demonstrated the impact of genetics on recovery
following injury to the CNS. While a number of clinical studies
have attempted to understand how genetics influences recovery
from brain injury in the human, this field is still at a very early
stage. Recovery from TBI represents a very complex phenotype. A
limitation of much work to date has been a reliance on candidate
gene studies with limited numbers of patients, some of which
have not proven reproducible10,11. The Genetics Association in
Neurotrauma (GAIN) Consortium (https://intbir.nih.gov/node/45)
will produce the first GWAS to study biological mechanisms that
modulate response and recovery after TBI. Only recently have
large scale GWAS studies reported on recovery after stroke12,13.
These studies are illustrative of the challenges facing the field,
because they have identified candidate genes whose relevance to
post-injury recovery is unclear. The validation of these candidates
will require new approaches using human cells in vitro and whole-
organism studies in model systems.
Although recovery from injury to the CNS takes place in a very
different environment and under very different circumstances to
brain development, many developmental processes, including
neurogenesis, axon sprouting and elongation, synaptogenesis,
and synaptic remodeling, are all critical to restoration of function
in TBI in the postnatal CNS14. Indeed, many genes implicated in
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neural recovery in animal and human studies have essential roles
in brain development. Over the past several years, the application
of next-generation sequencing technologies to the study of
developmental disorders has resulted in the identification of many
novel genes that have important roles in human brain develop-
ment15–17. It is reasonable to expect that variants in these
neurodevelopmental genes will influence brain repair in the adult.
It is also clear that apparently normal individuals may carry
mutations in such genes, and that the effect of a developmental
mutation in such an individual might be unmasked following
brain injury, because the environment in the adult is not as
supportive of neurogenesis or plasticity as that in embryonic or
fetal life.
This review considers the genetics of recovery from TBI from a
developmental standpoint. We include some informative studies
on spinal cord injury. Although the pathobiology of TBI is quite
different to injury in stroke, there are some overlaps in recovery
mechanisms, so we consider some relevant studies in stroke as
well. In this broad survey of the field, we refer to previous reviews
and meta-analyses of particular topics where appropriate, and the
citation of primary literature is focused on recent data and areas
that we have chosen to highlight.
NEUROBIOLOGICAL BASIS OF RECOVERY FROM CNS INJURY
Injury caused by trauma or stroke sets in motion a number of
processes that have the potential to repair or circumvent the
damage caused by the injury18,19. For example, the sensory and
motor cortex can undergo remapping to transfer function to
unaffected areas. Regrowth of fibers from the side contralateral to
a lesion can contribute to movement on the ipsilateral side
following injury. Behavioral activity interacts with these repair
processes, and activity- and experience-dependent plasticity are
important to functional recovery. At the cellular level, recovery
mediated by the remapping of neural circuits requires axon
sprouting, outgrowth, spine morphogenesis, synaptogenesis, and
synaptic pruning. Neurogenesis can enhance recovery in model
organisms20 and may play a role in humans as well, though the
extent to which neurogenesis continues during adult life in
primates remains controversial (below). Whatever the role of
neurogenesis in the adult human, it is apparent that the overall
capacity for remodeling and plasticity diminishes with aging21.
Axonal sprouting is fundamental to the rewiring that must
occur to bypass damage within circuits. Sprouting can forge new
connections around the lesion and on the contralateral side.
Axonal sprouting cannot be measured clinically, but primate
studies have established that it is part of the post-injury response
in monkeys22. Myelinated fiber tracts may also undergo injury and
subsequent incomplete repair23. The recovery process invokes
many biological strategies involved in learning and memory,
including long term potentiation and dendrite formation24. Tonic
(extrasynaptic) GABA inhibitory activity can be reversed to
enhance recovery. AMPA receptors stimulate BDNF release and
enhance learning and memory post-injury. Enhancing plasticity
early on may worsen outcomes, but later on, will enhance
recovery. Oligodendrocyte precursor cell activation may promote
remyelination.
These repair phenomena occur in an adult brain environment
that is hostile to rewiring, because it expresses inhibitors of axon
regeneration, including myelin-associated proteins, chondroitin
sulphate proteoglycans, and guidance molecules. Myelin asso-
ciated proteins and chondroitin sulphate proteoglycans constrain
axon outgrowth, and guidance molecules limit axonal growth
cone activity. Experimentally, interfering with of these inhibitory
pathways can have profound effects on outcome25. The regen-
erative niche is transient and unique to the injured brain. Recent
studies suggest that widespread rejuvenation of the adult CNS
environment through cell therapy can promote repair processes.
In spinal cord injury, transplantation of embryonic neural
progenitor cells can overcome limitations of axonal growth to
establish neural bridges across an injury zone26,27. Engraftment of
neural progenitor cells in this model results in prolonged
maintenance of a regenerative transcriptome in host neurons
that resembles a reversion to an embryonic state28.
In animal models, expression of neurotrophic and growth
factors is increased after injury, accelerating neurogenesis20,29.
Neurogenesis has the potential to replace damaged cells, but can
also provide for enhanced recovery through paracrine effects,
because neuroblasts, in addition to their potential for replacing
damaged cells, can promote a remodeling environment. It has
been demonstrated that interference with hippocampal neuro-
genesis will impair functional recovery after TBI in some
experimental paradigms30–32.
Whether or not neurogenesis takes place in the adult human is
currently controversial. Some studies have failed to demonstrate
proliferating cells in the adult CNS, whilst others have demon-
strated their presence in an equally convincing fashion, and the
basis for the discrepancies in these studies remain unresolved33–36.
Whatever its role in the adult, neurogenesis is almost certainly
relevant to repair of injury or ischemic damage in the neonatal or
pediatric context, and it may be that quiescent stem cells exist in
humans that may be called into action in the face of injury. In mice,
aging brains have quiescent stem cells kept in a dormant state by
inflammatory signals and antagonism of the Wnt pathway37,38.
Nonetheless, these cells can be activated by injury.
Microglia play an active role in recovery from damage to the
CNS including TBI39. These innate immune cells can participate in
clearance of debris after injury, remodeling, neurogenesis,
angiogenesis, oligodendrogenesis, and remyelination. However,
microglia can also have a detrimental effect, through the
production of inflammatory or neurotoxic cytokines. Polarization
of microglia has been well documented, and as in other tissues, a
generalization is that M2-like cells play a role in all repair
processes. Recently Willis et al. showed that enhancing turnover of
microglia either through genetic depletion and replacement or
pharmacologic manipulation considerably enhanced recovery
after TBI, through increased neurogenesis mediated by an IL6
response40.
BRAIN REPAIR AND DEVELOPMENTAL PATHWAYS
Many developmental pathways are involved in the repair of injury
to the CNS; neurogenesis, axonal sprouting, and growth factor
dependence characterize both development and regeneration.
There are clear differences between axon sprouting in develop-
ment and in repair in the adult CNS. The axon sprouting that
occurs in response to stroke is associated with a different
transcriptome than that seen during development, and it changes
with age41. However, a number of key developmental regulators
are known to function in repair in the adult CNS (Fig. 1).
Neuroplasticity is key to repair in the CNS. In searching for
sources of genetic variation in CNS repair capacity, it is worth
considering new findings regarding neurodevelopmental genes.
Human studies have shown that disruption of processes involved
in neuronal plasticity are characteristic of childhood neurological
disorders caused by mutations in neurodevelopmental genes.
MECP2, FMR1, TSC1 and 2, UBE3A, and NF1 all affect dendritic
spines and synapse morphology. TOR1A influences synaptogen-
esis in the cerebellum, and SHANK3 modulates the expression of
receptors for AMPA and NMDA and in turn impacts on plasticity,
specifically long-term potentiation. ATXR is a developmental gene
that controls neuron survival and migration, and assists in growth
cone formation. A survey of gene networks impacted by
developmental disorders shows that chromatin remodeling, cell
proliferation and migration, synaptic networks, and long-term
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potentiation are often targeted in autism spectrum disorders16. All
of these processes are critical to plasticity.
Deleterious variants in neurodevelopmental genes could
greatly impact brain repair after TBI. Copy number variations
and single nucleotide variants that are associated with neuro-
developmental disorders often show variable penetrance or
expressivity, and individual phenotypes are influenced by
genetic background and modifier effects42. It is easy to imagine
that patients bearing such mutations who do not show a
developmental phenotype might be impaired in recovery
processes in the adult, where the environment is less favorable
to plasticity. These variants would be relatively rare and would be
expected to have intermediate effect, characteristics that would
hamper their discovery through GWAS.
GENETIC STUDIES IN MICE
There are three lines of evidence from studies in mice that show
the impact of genetics on the recovery from damage to the CNS.
First, some reports have identified differences between mouse
strains in recovery in various models of brain injury. Second,
reverse genetic studies that interrogate the effects of deletion of
candidate genes on CNS recovery have provided evidence for
positive and negative regulation of neural repair. Finally, a few
forward genetic screens have been carried out to identify new loci
involved in the CNS recovery response. We discuss some examples
of all three types of investigation43.
There is evidence for strain-dependent differences in inherent
capacity for functional recovery after CNS injury, with some findings
highlighting axon growth and the inflammatory response in
Fig. 1 Damage and Repair at the Cellular Level in the Central Nervous System. A Traumatic injury through shearing or crushing action leads
to Wallerian degeneration distal to the site of injury and accompanying demyelination; retrograde degeneration leads to chromatolysis with
swelling of the cell body, nuclear displacement, fragmentation of the rough endoplasmic reticulum and metabolic changes. Synapses
withdraw, and glial infiltration and proliferation ensue. These effects on synapses can affect neurons in circuits either upstream or downstream
from the injured cell. B Neurogenesis is enhanced by injury in animal model systems in the subventricular zone and in the hippocampus. The
extent to which neurogenesis occurs in the adult human is unclear, though it is known in model systems that quiescent neural stem cells can
undergo activation in the adult. Glia and endothelial cells can modulate neurogenesis. C Connectivity may be restored by outgrowth of
neurites, axon formation, dendritogenesis, and synaptogenesis. In the CNS, these processes may be limited by a non-permissive environment.
D Synaptic pruning refines and strengthens connections. E Collateral sprouting can find new routes in spinal tracts to avoid a lesion zone. NSC
neural stem cells, NPC neural precursor cells, TAC transient amplification cell.
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mediating the recovery process. A study of four strains given
contusion injury to the spinal cord showed better recovery of
function in C57Bl/10 and B10.Pl mice relative to C57Bl/6 or BALB/c44.
In another study of a spinal cord injury model, better axonal growth
into the lesion area was observed in 129 × 1/SvJ mice, and this was
associated with a decreased chronic inflammatory response relative
to C57Bl/645. There were fewer macrophages in the lesion of 129 ×
1/SvJ animals, more neurons and astrocytes, increased levels of
laminin, and lower levels of CSPG. A third spinal cord injury reported
that 129 × 1/SvJ mice displayed better corticospinal axon extension
relative to C57Bl/625. Axon regeneration was enhanced in both
strains on a Nogo−/− background. The strain differences were
reflected in an in vitro study of dorsal route ganglia neurite
outgrowth. Again, more macrophages persisted in the lesions of
the C57Bl/6 animals. Differentially expressed genes in the two
strains were associated with neurite growth, synapse formation,
inflammation, and immune response. A recent study on oxidative
stress in rat neuronal cultures revealed strain differences in the
innate neuronal response that might reflect the ability to adapt to
an inflammatory environment46.
Much previous work has addressed the effect of gene knock-
outs on neuroprotection or sensitization of the mouse brain to
injury. A more limited number of experiments in mice have
examined the effect of knockouts of specific genes on recovery
from CNS injury. Many of these have focused on extracellular
signaling molecules or their receptors. For example, studies have
shown that genetic ablation of factors that block neurite extension
can enhance recovery. Mice deficient in Nogo A B or C, myelin
enriched inhibitors of neurite outgrowth, show enhanced
regeneration of the corticospinal tract following SCI25. Knockdown
of Epha4, a widely expressed ephrin receptor that is an inhibitor of
growth cones, enhanced regrowth of descending axons after SCI
and had a similar effect in stroke models47. Inhibition of its
downstream target, Rho-associated kinase had a similar effect.
The capacity for axonal regeneration declines with age in mice,
and at least part of this decline is associated with an age-related
decline in the MTOR pathway driven by the negative MTOR
regulator Pten. Pten is strongly inhibitory to axonal sprouting, and
deletion of this gene can enhance sprouting and recovery from
CNS injury. Pten and Socs3 knockout improved sprouting of
corticospinal axons and recovery of limb motor control48.
Conditional deletion of Pten after spinal cord injury enhanced
recovery and accelerated axon outgrowth49. The effect of Pten
deletion on regrowth of corticospinal axons persisted for up to
one year following an injury50. However, Pten deletion in older
mice was less effective in enabling axonal regeneration, perhaps
due to increased microglia and astrocyte activation in the aged
animals21. In another study of aging and the regeneration,
administration of Osteopontin to adult mice enhanced IGF1
responsiveness in an axon sprouting assay back to levels seen in
young animals, and the combination promoted regrowth of the
corticospinal tract51.
GDF10 is a TGF beta superfamily member that is induced in the
peri-infarct region in stroke. This growth factor has been reported
to promote neural outgrowth and functional recovery in stroke
models. GDF10 induced a unique stroke transcriptome that
differed from postnatal (P4) developing brain52. GDF10 adminis-
tration increased axonal sprouting in the adult and enhanced
functional recovery from stroke. This effect of GDF 10 was
mediated through down regulation of Pten and upregulation of
axonal guidance molecules.
Inhibition of CCR5 receptor signaling was shown to enhance
learning, memory, and plasticity in the hippocampus and cortex53.
Knockout of this gene was associated with faster recovery of
motor control in a stroke model and better recovery of cognitive
function in a TBI model54. The effect could be phenocopied by the
chemical knockdown of CCR5 signaling. Deletion of CCR5
preserved dendritic spines, and established new projections to
the contralateral cortex. In a human study, Joy et al. exploited
polymorphisms in this gene to show that a loss of function was
associated with faster recovery from stroke54.
These and other studies of the role of specific genes in recovery
from CNS damage are described in Table 1. For each study, the
table lists the biological processes most affected by the gene in
question, the functional outcome assessed, and the underlying
changes at the cellular level. It is important to distinguish these
studies from ones that are designed to discover naturally
occurring genetic variants that affect recovery from injury, such
as those focused on strain differences discussed above. It is also
important to remember that gene deletion studies performed in
one strain may be subject to strong genetic modifier effects, such
that the response of different strains to gene deletion may be
quite divergent.
In the past, most studies of recovery in the CNS in mice have
relied on a few inbred strains. Mouse genetic diversity panels
provide for a much broader interrogation of the effect of genetic
background on recovery and for improved modeling of human
disease. In a study of the eight founder strains of the Collaborative
Cross55, dorsal root ganglion neurons from CAST/EiJ (derived from
a strain of wild mice) showed the highest capacity for axonal
growth on an inhibitory matrix of CNS myelin in vitro. In three
in vivo models of CNS injury, dorsal root ganglion regrowth, optic
nerve injury, and ischemic stroke, CAST/EiJ showed better axonal
outgrowth. Further investigation of gene expression in strains with
high medium and low capacity for outgrowth showed that the
differences were mediated by the degree of induction of inhibin/
Activin A. A follow-up study also found an up-regulation of Ascl1
due to a down-regulation of miR-7048-3p in Cast/Ei, a phenotype
that increased neurite outgrowth in the dorsal root ganglion after
axonal injury56. Loss and gain of function experiments in vitro and
in vivo confirmed this activity.
HUMAN STUDIES
The advantage of working with model systems include uniformity
of age, sex and genetic background, well-controlled reproducible
injuries, controlled environment, and quantitative uniform end-
points. There are many challenges to clinical studies of recovery
from TBI, including the size and diversity of the patient cohorts,
heterogeneity of injuries, variations in post-injury environment,
care and management, a diversity of endpoints analyzed, and
wide variations in the time of follow-up. Most studies report
medium- or longer-term outcomes. The Glasgow Outcome Score
(GOS) is a widely though not universally used metric. Recovery
from injury to the CNS is not a simple endpoint and clinical
outcomes could be influenced by a diversity of biological and
pathological processes.
Most of the human studies reported to date are retrospective
and were centered on candidate genes that are either hypothe-
sized to influence recovery after TBI or are involved in related
pathological processes. Important selection biases in these studies
relate to gender, race, and ethnicity. It is known that males tend to
participate in hazardous activities more often than women, such
that on average in TBI studies, only one-third of the patients are
females. Genetic studies of TBI outcome in humans, like many
studies of genetic association with disease, have been biased
towards inclusion of Caucasian individuals. It is important to
overcome this limitation for scientific reasons57, and to ensure
equitable access to innovations in health care. Here we focus on a
few of the most widely studied genetic polymorphisms and
thereafter discuss several very recent GWAS analyses of recovery
from stroke. A summary of results from work on the more widely
studied candidate genes is provided in Supplementary Table 1.
These studies illustrate the challenges in reaching general
conclusions from such studies, owing to variability in outcome
D. Cortes and M.F. Pera
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measures, clinical endpoints, mode of assessment, and subject
characteristics.
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
BDNF belongs to the neurotrophin family of growth factors and
exerts its actions through binding to TrkB and the p75 receptor.
BDNF is widely expressed in the central nervous system (CNS), and
it plays pleiotropic roles in a number of processes during
development and adult life, including neurogenesis, glutamatergic
and GABaergic signaling, neuritogenesis, and long-term potentia-
tion. This neurotrophin has also been one of the most widely
studied genes in the context of TBI and stroke, because of the
existence of a genetic variant with known functional conse-
quences. A common single nucleotide polymorphism (SNP) within
the coding region of BDNF gene found in 30–50% of the
population results in the substitution of valine (Val) with
methionine (Met) at codon 66 in the prodomain of the protein
(Val66Met). The amino acid variant interferes with the sorting and
secretion of the factor, resulting in a decrease in its activity-
dependent release, which impacts on all downstream processes
modulated by this factor. This phenotype diminishes BDNF protein
secretion and growth cone retraction, critical to axon extension58.
The role of BDNF and its polymorphisms is one of the most
intriguing examples of the potential impact of genetics on the
CNS in health and disease. In physiological conditions, the
66met allele has been associated with lower cognitive perfor-
mance59, and less gray matter volume, and it has been implicated
in pathologies such as Alzheimer’s disease60 as well.
However, the role of BDNF in recovery from TBI or stroke has been
controversial. A meta-analysis in stroke patients found the Val66Met
phenotype to be predictive of poor outcome with an Odds Ratio (OR)
of 2.6061. In another study, Met-carriers were reported to show poor
recovery after stroke but not TBI62. In fact, several studies carried out
on war veterans after decades post-TBI showed that Met variant of
rs6265 BDNF has better preservation of general intelligence and
executive functioning after prefrontal cortex (PFC) damage63. In
another report, BDNF was found to be the second most consistent
predictor of cognitive status after TBI, just after intelligence prior to
injury64 (known as the best predictor for recovery). The rs7124442
and rs1519480 SNPs were also found to be associated with post-
injury recovery of general intelligence on combat veterans with focal
penetrating TBI after 15 years of the event. In a pediatric study65,
patients with the rs6265 variant had a better behavioral outcome at
6 months post-TBI. However, that difference disappeared at
18 months.
As noted above, Val66 carriers have been shown to perform
better in cognition and to show better outcomes in neurodegen-
erative diseases compared to Val66Met individuals. The explana-
tion of these differences in some of these studies might reside in
the area impacted by the lesion, the different effects of pro-BDNF
and BDNF, and changes in p75NTR and TrkB expression. Not only
BDNF but pro-BDNF can be secreted, and the two forms show
different binding affinities to their receptors. The high-affinity
receptor TrkB binds BDNF preferentially, and the low-affinity
receptor p75NTR binds pro-BDNF. Binding to Trkb is associated
with pro-survival actions, but binding to p75NTR is pro-apoptotic.
The expression levels of both forms of BDNF and pro-BDNF, as
well as TrkB and p75NTR, can change their expression ratio during
life and neurological illnesses. These complexities may account for
the disparate outcomes observed.
Advanced age is well-known to impact negatively on TBI
outcome. Failla et al.66 examined the rs6265r (Val66Met) and
rs7124442 SNP (T > C, which impairs trafficking of the BDNF
transcript) of the BDNF gene in the context of TBI in patients of
different ages. It was found that these polymorphisms interact
with age and modify mortality rate after severe TBI. During the
acute phase, the anticipated low-risk group (predicted to be Val
and 7124442 C) had the lowest survival rate. In the post-acute
phase and as expected, the low-risk phenotype had the highest
survival rate. However, this was not true for older patients. It
seems that during aging the BDNF signaling and its response
against injury might change due to SNPs within the gene itself,
the BDNF receptors, or any other transcriptional factor associated
with the signaling pathway.
Severe TBI can induce coma and the vegetative state. Since
BDNF is present in several brain areas, participates in many neural
activities, and its polymorphisms are associated with functional
variations in neuronal activity; it is reasonable to hypothesize that
genetic variation at this locus might influence recovery from
vegetative state. Nonetheless, a homogenous sample of patients
with this condition after TBI and with val66met variation did not
show differences in recovery of consciousness or cognitive
improvement67. An explanation for the absence of association
could be caused by a “point of no return” due to extensive and
irreparable damage in the brain.
The variability in the outcomes of these studies thus highlights the
likely interaction of genes, environment, and age with the nature of
injury and the endpoints under study. Thus, the studies above need
to be interpreted cautiously. Future research will have to use
polygenic approaches, next generation sequencing, gene-set enrich-
ment analysis, and, machine-learning-assisted analysis, to finally
unravel the true relation of BDNF polymorphisms and TBI.
APOLIPOPROTEIN E (APOE)
Apolipoprotein E protein is a principal constituent of blood
lipoprotein transporter. There are three main alleles of APOE, 2, 3,
and 4, 3 being the most common one. The ApoE4 allele has been
associated with Alzheimer’s Disease, amyloid deposition, impaired
cognition, and other neurological conditions, including recovery
from TBI (review),68. The basis for the widespread involvement of
this ApoE allele in diverse disorders of the CNS is not clear.
It has been difficult to reach firm conclusions regarding the
impact of APOE genotype on recovery from TBI; the size of the
patient cohorts, patient age, the type and extent of lesion, clinical
endpoints, and statistical analysis has been quite variable across
many studies, and undoubtedly these factors have confounded the
interpretation of the data. The APOE genotype can also impact on
co-morbidities which may differ from global outcomes.
Nevertheless, meta-analyses of the effect of APOE4 status point
towards a role in recovery, while illustrating how additional variables
can affect the outcome. A meta-analysis conducted in 201569
indicated that the adverse effects of APOE4 carrier status were more
pronounced in pediatric TBI than in adults. The OR for a poor
outcome of childhood TBI in E4 allele carriers relative to the
remaining population-averaged 2.36 across the studies. A second
meta-analysis also reported in 201570 began with 42 potentially
eligible studies but excluded 30, mostly on the grounds that they did
not use standard endpoints. A significant effect was found for long-
term (>6 months) outcomes only with E4 carriers showing increased
risk of a poor outcome with an overall OR around 1.4. A meta-analysis
published in 201971 found a worse outcome in APOE4 carriers with
an OR of 1.39. Finally, one meta-analysis72 found no correlation
between APOE4 genotype and cognitive outcome following TBI.
The difficulties are illustrated by consideration of a few
individual studies. Moran and colleagues studied a cohort of
children, and they could not find any differences other than a
lower GCS (Glasgow Coma Scale) in APOE4 carriers73. Ponsford
and colleagues74 only found an association between ApoE4 and
worst GOSE (Glasgow Outcome Score), especially among women.
However, they could not find lower GCS or post-traumatic
amnesia (PTA) associated with ApoE4. Merritt et al. found that
the ApoE4 genotype was associated with high levels of psychiatric
distress in veterans75. Interestingly, the lack of association of
ApoE4 genotype with outcomes has been shown in different
D. Cortes and M.F. Pera
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populations such as African, British, and Indian76–78. Future studies
will need to look closely at how genetic background modulates
the effect of ApoE4 genotype of individual response, as recently
noted in a study in mice79.
DOPAMINERGIC SYSTEM
The dopaminergic system plays a variety of roles in the CNS
including the regulation of mood, cognition, behavior, reward, and
executive function involving pathways such as the mesocortical and
mesolimbic tracts. Recent studies have addressed the effects of
polymorphisms in dopaminergic-associated genes such as dopamine
receptor 2 (DRD2), Ankyrin repeated kinase domain containing 1
(ANKK1), Solute carrier family 18 member A2 (SLC18A2), dopamine
transporter (DAT) and Catechol-O-methyl transferase (COMT) in TBI.
DRD2 is a G protein-coupled receptor that is involved in
memory formation and synaptic plasticity, and it is a crucial
receptor of many antipsychotic drugs. ANKK1 is serine/threonine
kinase found in astrocytes and plays a considerable role in
modulating dopaminergic reward processes. ANKK1 is also closely
linked to DRD2 expression as rs1800497 polymorphism with a
single T allele reduces DRD2 expression in the ventral striatum by
30–40%. Failla et al. found that SNPs in two adjacent genes,
ANKK1 rs1800497 and DRD2 rs6279 were associated with
cognitive outcome after severe-TBI at 6-months80. However, at
12-months only ANKK1 remained significant, and after adjusting
for multiple testing no significant associations could be main-
tained. The combination of two prospective multicenter studies
analyzing the TBI outcome at six months concerning cognitive
function showed that rs1800497 T/T patients had the worst
outcome compared to C/T and C/C patients81.
Recently, Treble-Barna and colleagues82 analyzed a control group
vs. a TBI cohort of children and followed them up to seven years. A
total of 32 SNPs were analyzed across different dopamine-related
genes. Genetic variation within SLC18A2, including rs464040 and
rs460000 were associated with short- (6 months) and long-term (up
to seven years) impairment following injury. In the case of ANKK1
rs1800497 and rs2734849, an association was found only for short-
term impairment. Behavioral deficits in short- and long-term
memory exhibited interactions with SLC18A2 rs464049, long-term
deficits with rs1042098, and executive deficiencies within the short-
time period with rs464049 and rs460000. In the same study there
was no association with outcome and COMT and DRD2 genotypes;
however, the rs1800497 SNP in ANKK1 gene exhibited high
interaction, with the poorest outcome in TBI in children. As noted
above, it is known that ANKK1 is closely related to DRD2 and
polymorphisms in the former can affect the latter; actually, people
with this polymorphism display lower dopamine receptor density,
hence lower ligand binding. The rs6277 allele which is a C947T
polymorphism within the DRD2 gene was analyzed in a Caucasian
sample of TBI patients and followed up to 6 months81. These
researchers found that this SNP confers verbal learning improve-
ment without mental flexibility or processing speed. The result
suggests that this receptor’s effects are not global but limited to
areas where it is highly expressed such as basal ganglia. Projections
from this area connect to memory- and learning-related regions in
subcortical prefrontal and hippocampal zones.
A meta-analysis of DRD2, ANKK1, SLC18A2, and COMT
polymorphisms assessed which of the SNPs actually influence
the expression abundance activity or affinity of the cognate
protein product83. DRD2 splicing was affected by the rs1076560
variant, and ligand binding of DRD2 was affected by the
rs1800497 polymorphism in ANKK1. The Val158met polymorphism
in COMT had marked effects on the abundance and stability of the
protein and on its enzymatic activity. Analyses of this nature are
very helpful in prioritizing variants for further study. Thus,
Nekrosius et al. found an association of increased risk of delirium
after TBI in patients with the rs4680 mutation (Val158Met84).
VARIANTS IN OTHER PATHWAYS
Variants in a number of other genes have been reported
(generally in modest-sized studies) to impact on the recovery
from TBI in patient studies. These are summarized in Supplemen-
tary Table 2. Some of the pathways that have been investigated in
multiple studies include glutamatergic transmission, purinergic
transmission, immunomodulation, and solute and water transport.
As with the clinical studies discussed above, there is great diversity
in outcome measures, clinical endpoints, mode of assessment, and
subject characteristics. Single studies of common polymorphisms
with limited follow-up have limitations, but the outcomes of these
works may hold clues for future studies.
RECENT GWAS STUDIES OF FUNCTIONAL OUTCOME OF
STROKE
Two recent GWAS studies have identified candidate genes for the
determination of functional outcome after stroke. The GISCOME
meta-analysis study12 assessed over six thousand patients using
a modified Rankin Scale that evaluates the extent of disability at a
60–190 day time point. Interestingly, the strongest variant was in a
trans-QTL locus controlling PPIR21, a regulatory subunit of protein
phosphatase 1 involved in neural plasticity, similar to PPP3CC
(Supplementary Table 2). Other possible variants identified were
NTN4 (netrin 4) an axon guidance molecule, TEK (a protein kinase
receptor for angiopoietin 1), and PTCH1 (Hedgehog receptor).
The identification of these molecules leads to testable hypotheses
regarding their function in brain repair, through neuronal or
vasculature processes. A second GWAS meta-analysis13 included a
discovery, replication, and joint phase to study associations with
recovery measured again on the Rankin Scale. This study identified
PATJ, a gene encoding an epithelial tight junction protein. The
relationship of this gene to biological recovery post-stroke is
uncertain. As with other GWAS studies, epigenetics and the
environment will interact with clinical variables to determine the
association of a variant with recovery from brain injury, and
the association is not proof of causality. Additional analysis of the
epigenome, transcriptome, and proteome will further refine conclu-
sions from large-scale studies. However, the application of GWAS to
recovery from TBI represents an unbiased approach to identify new
genes and pathways that can be subjected to functional analysis
through in vitro testing and in animal models.
CONCLUSIONS AND FUTURE DIRECTIONS
Recovery from brain injury invokes a number of processes involved
in neurodevelopment. We do not yet fully understand how these
processes operate in the context of injury in the adult organism. The
activities of the innate and acquired immune systems are a key
difference between the two. Nonetheless, emerging human genetic
data on the function of neurodevelopmental genes in plasticity will
inform studies of gene network function in adult brain repair. Studies
in mice provide strong evidence for a genetic basis of strain
differences in the recovery from TBI or stroke, and have identified a
number of genes that clearly influence key processes in recovery.
However, most of these genes (with the exception of CCR5) have not
been identified in human studies of interindividual variation in
recovery. There are many challenges to examining the genetic basis
of recovery from brain injury in humans, and the results of many
studies performed to date are not really conclusive. The evidence
suggests that BDNF and APOE loci are involved in recovery from TBI
or stroke, but recent GWAS studies in stroke recovery have failed to
implicate either. Indeed, the recent GWAS studies have brought
forward new candidates but these will require validation and further
analysis.
The application of unbiased genetic approaches to identify
genes and gene networks involved in recovery from CNS damage
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has just begun. A coordinated approach using human and mouse
cell-based screens, along with whole-organism studies in mice,
will enable rigorous assessment of candidate regulatory factors
and networks, and provide new targets for pharmacologic or
cellular interventions to enhance recovery. These components, in
conjunction with careful and adequately powered clinical studies,
will help to enable a precision medicine approach to neuroreh-
abilitation and repair.
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